Computational docking models and pull-down assays confirmed dronedarone's direct binding to CDK4 and CDK6, inhibiting their kinase activity and subsequently reducing RB1 phosphorylation at ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

Cyclin D1–CDK4/6 phosphorylates GTSE1 in cancer cells, preventing its degradation and sustaining high levels across the cell cycle, which enhances proliferation and correlates with poor prognosis.

Their findings demonstrate that miR-377 effectively targets MYC mRNA, as confirmed by luciferase assay and Real-time PCR. They observed a significant reduction in BCL-2 and CDK4 expression ...

"While we await results from ongoing prospective trials, our data suggest that treatment decisions should consider both the prior history of CDK4/6i benefit and the pattern of metastatic spread." ...